Bilateral Anterior Segment Hyphema and Ocular Hypotony Following Treatment with Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto).

IF 2.6 4区医学 Q2 OPHTHALMOLOGY

Ocular Immunology and Inflammation Pub Date : 2025-05-19 DOI:10.1080/09273948.2025.2504582

Roger K Henry, Miriam Habiel, Aretha Zhu, Glen Gejerman, Albert S Khouri, Jonathan C Tsui

{"title":"Bilateral Anterior Segment Hyphema and Ocular Hypotony Following Treatment with Lutetium (177Lu) Vipivotide Tetraxetan (Pluvicto).","authors":"Roger K Henry, Miriam Habiel, Aretha Zhu, Glen Gejerman, Albert S Khouri, Jonathan C Tsui","doi":"10.1080/09273948.2025.2504582","DOIUrl":null,"url":null,"abstract":"Purpose: We describe a case of severe bilateral anterior segment neovascularization leading to hyphema in a patient treated with Lutetium (177Lu) vipivotide tetraxetan for metastatic castration-resistant prostate cancer (mCRPC).Methods: Case report with multimodal imaging.Results: A 77-year-old patient was referred for evaluation of a two-day history of blurry vision. At presentation, the exam was significant for bilateral hyphema, elevated intraocular pressure, and significant microcystic edema. Gonioscopy revealed neovascularization of the anterior segment. Multimodal imaging revealed intraretinal hemorrhages without neovascular retinopathy, metastases, or carotid occlusive disease. The patient was treated medically, but developed significant hypotony necessitating postponement of therapy.Conclusion: This case demonstrates a potential ocular adverse reaction to Lutetium (177Lu) vipivotide tetraxetan therapy.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-4"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2025.2504582","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: We describe a case of severe bilateral anterior segment neovascularization leading to hyphema in a patient treated with Lutetium (177Lu) vipivotide tetraxetan for metastatic castration-resistant prostate cancer (mCRPC).

Methods: Case report with multimodal imaging.

Results: A 77-year-old patient was referred for evaluation of a two-day history of blurry vision. At presentation, the exam was significant for bilateral hyphema, elevated intraocular pressure, and significant microcystic edema. Gonioscopy revealed neovascularization of the anterior segment. Multimodal imaging revealed intraretinal hemorrhages without neovascular retinopathy, metastases, or carotid occlusive disease. The patient was treated medically, but developed significant hypotony necessitating postponement of therapy.

Conclusion: This case demonstrates a potential ocular adverse reaction to Lutetium (177Lu) vipivotide tetraxetan therapy.

查看原文本刊更多论文

黄体（177Lu） Vipivotide Tetraxetan （Pluvicto）治疗双侧前段前房积血和低眼压。

目的：我们描述了一例严重的双侧前段新生血管导致前血积血的病例，该患者接受了Lutetium (177Lu) vipivotide tetraxetan治疗转移性去势抵抗性前列腺癌（mCRPC）。方法：采用多模态影像学检查。结果：一名77岁的患者被转介评估其视力模糊的两天历史。在就诊时，检查有明显的双侧前房积血，眼压升高和明显的微囊性水肿。关节镜检查显示前节新生血管。多模态影像显示视网膜内出血，无新生血管性视网膜病变、转移或颈动脉闭塞性疾病。患者接受了医学治疗，但出现了明显的低血压，需要推迟治疗。结论：本病例显示黄体（177Lu） vipivotide tetraxetan治疗有潜在的眼部不良反应。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.